文献类型：期刊文献

中文题名：基于HPLC及生物信息学探究淫羊藿-黄芪防治少弱精子症的药效物质及作用机制

英文题名：Exploring the pharmacodynamic substances and mechanisms of epimedii folium-astmgali radix in the prevention and treatment of oligoasthenospermia based on HPLC and bioinformatics

作者：李彦荣[1];陈振东[1];陈静[1];颜鲁林[1];郭文龙[1];赵晶[2];蒋宜伟[1]

第一作者：李彦荣

机构：[1]甘肃中医药大学,甘肃兰州730000;[2]定西市人民医院,甘肃定西743000

第一机构：甘肃中医药大学

年份：2025

卷号：39

期号：2

起止页码：34

中文期刊名：中国男科学杂志

外文期刊名：Chinese Journal of Andrology

基金：国家自然科学基金项目(82360905,82160916);甘肃省自然基金项目(21JR1RA268);定西市科技计划资助(DX2021AZ04)。

语种：中文

中文关键词：淫羊藿;黄芪;色谱法;高压液相;网络药理学;分子对接模拟;少精子症;弱精子症

外文关键词：epimedii folium;astmgali radix;chromatography;high pressure liquid;network pharmacology;molecular docking simulation;oligospermia;asthenozoospermia

摘要：目的明晰淫羊藿-黄芪防治少弱精子症的药效物质和溶出与配比的相互关系、作用机制及理论效果。方法HPLC法测定淫羊藿-黄芪不同配比时主要药效物质含量。GeneCards和UniProt数据库获得少弱精子症靶点基因,TCMSP数据库筛选淫羊藿-黄芪主要化学成分及对应靶点基因,Cytoscape软件构建药物-活性成分-关键靶点调控网络,STRING平台筛选关键蛋白靶点,DAVID数据库对共同靶点进行GO功能及KEGG通路富集分析,PDB数据库和PyMOL、AutoDock Vina软件进行分子对接验证淫羊藿-黄芪干预SCF/c-kit信号通路防治少弱精子症的效果。结果淫羊藿-黄芪药效物质溶出与药物量呈正相关。筛选出淫羊藿核心成分有MOL000006、MOL004380、MOL004373、MOL004391、MOL003542等,黄芪核心成分有MOL000378、MOL000392、MOL000354、MOL000296、MOL000371、MOL000380、MOL000417等,共有核心成分有MOL000098、MOL000422;关键核心靶点有AKT1、TP53、TNF、JUN、IL1B、ESR1、CASP3、HIF1A、PTGS2、EGFR、MYC、HSP90AA1、MMP9、PPARG、FOS、CCND1、PTEN、CXCL8、ERBB2、SIRT1、CCL2、IL10等;富集分析淫羊藿-黄芪活性成分防治少弱精子症与AGE-RAGE、IL-17等信号通路相关。分子对接结果提示朝藿定C、芒柄花苷等化学成分与SCF/c-kit等靶蛋白有强烈的结合能力。结论初步揭示了淫羊藿-黄芪药对不同配比时的主要活性成分变化,淫羊藿-黄芪可能通过多成分、多靶点、多通路协同防治少弱精子症,且有良好的疗效。本研究为淫羊藿-黄芪防治少弱精子症的分子生物学研究和临床用药提供了参考。
Objective To clarify the pharmacodynamic substances,the relationship between dissolution and ratio,as well as the mechanisms and theoretical effects of Epimedium-Astragalus in the prevention and treatment of oligoasthenospermia.Methods The major pharmacodynamic substances of Epimedium-Astragalus in different ratios was determined by high-performance liquid chromatography(HPLC).The target genes related to oligoasthenospermia were obtained from GeneCards and UniProt databases.The main chemical components and corresponding target genes of Epimedium-Astragalus were screened using the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform(TCMSP).A drug-active component-key target regulatory network was constructed using Cytoscape software.Key protein targets were identified on the STRING platform.Gene Ontology(GO)functional and Kyoto Encyclopedia of Genes and Genomes(KEGG)pathway enrichment analyses of common targets were performed using the Database for Annotation,Visualization and Integrated Discovery(DAVID).The Protein Data Bank(PDB)database,PyMOL,and AutoDock Vina software were used for molecular docking to verify the efficacy of Epimedium-Astragalus in the prevention and treatment of oligoasthenospermia via inactivating SCF/c-kit signaling pathway.Results The dissolution of pharmacodynamic substances from Epimedium-Astragalus was positively correlated with its drug quantity.The identified core components of Epimedium included MOL000006,MOL004380,MOL004373,MOL004391,and MOL003542,while those of Astragalus were MOL000378,MOL000392,MOL000354,MOL000296,MOL000371,MOL000380,and MOL000417.Common core components of the both were MOL000098 and MOL000422.Key targets included AKT1,TP53,TNF,JUN,IL1B,ESR1,CASP3,HIF1A,PTGS2,EGFR,MYC,HSP90AA1,MMP9,PPARG,FOS,CCND1,PTEN,CXCL8,ERBB2,SIRT1,CCL2,and IL10.Enrichment analysis revealed that the active components of Epimedium-Astragalus in preventing and treating oligoasthenospermia were associated with signaling pathways such as AGE-RAGE and IL-17.Molecular docking results indicated strong binding capabilities between chemical components such as epimedin C and formononetin and target proteins like SCF/c-kit.Conclusion This study preliminarily revealed the changes in major active components of Epimedium-Astragalus at different ratios.Epimedium-Astragalus may have good efficacy in preventing and treating oligoasthenospermia through a multi-component,multi-target,and multi-pathway synergistic mechanism.This research provides a reference for the molecular biological study and clinical application of Epimedium-Astragalus in the prevention and treatment of oligoasthenospermia.